215 related articles for article (PubMed ID: 36428997)
1. Upregulation of YKL-40 Promotes Metastatic Phenotype and Correlates with Poor Prognosis and Therapy Response in Patients with Colorectal Cancer.
De Robertis M; Greco MR; Cardone RA; Mazza T; Marzano F; Mehterov N; Kazakova M; Belev N; Tullo A; Pesole G; Sarafian V; Signori E
Cells; 2022 Nov; 11(22):. PubMed ID: 36428997
[TBL] [Abstract][Full Text] [Related]
2. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.
Tarpgaard LS; Guren TK; Glimelius B; Christensen IJ; Pfeiffer P; Kure EH; Sorbye H; Ikdahl T; Yilmaz M; Johansen JS; Tveit KM
PLoS One; 2014; 9(2):e87746. PubMed ID: 24498368
[TBL] [Abstract][Full Text] [Related]
3. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer.
Liu X; Zhang Y; Zhu Z; Ha M; Wang Y
Med Oncol; 2014 Aug; 31(8):85. PubMed ID: 24996799
[TBL] [Abstract][Full Text] [Related]
4. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue.
Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
Tumour Biol; 2014 Jan; 35(1):277-86. PubMed ID: 23918300
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer.
Oh IH; Pyo JS; Son BK
Curr Oncol; 2021 Aug; 28(4):3139-3149. PubMed ID: 34436040
[TBL] [Abstract][Full Text] [Related]
6. YKL-40 protein expression in human tumor samples and human tumor cell line xenografts: implications for its use in tumor models.
Böckelmann LC; Felix T; Calabrò S; Schumacher U
Cell Oncol (Dordr); 2021 Oct; 44(5):1183-1195. PubMed ID: 34432260
[TBL] [Abstract][Full Text] [Related]
7. Strong YKL-40 expression in the invasive tumor front of colorectal cancer-A pilot study.
Kazakova M; Ivanova T; Dikov D; Molander D; Simitchiev K; Sbirkov Y; Dzhambov AM; Sarafian V
Heliyon; 2024 Mar; 10(5):e27570. PubMed ID: 38495157
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
[TBL] [Abstract][Full Text] [Related]
9. YKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer.
Jefri M; Huang YN; Huang WC; Tai CS; Chen WL
BMC Cancer; 2015 Aug; 15():590. PubMed ID: 26275425
[TBL] [Abstract][Full Text] [Related]
10. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival.
Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
Cancer; 2002 Jul; 95(2):267-74. PubMed ID: 12124825
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer.
Bi J; Lau SH; Lv ZL; Xie D; Li W; Lai YR; Zhong JM; Wu HQ; Su Q; He YL; Zhan WH; Wen JM; Guan XY
Hum Pathol; 2009 Dec; 40(12):1790-7. PubMed ID: 19765801
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers.
Shao R; Cao QJ; Arenas RB; Bigelow C; Bentley B; Yan W
Br J Cancer; 2011 Oct; 105(8):1203-9. PubMed ID: 21934681
[TBL] [Abstract][Full Text] [Related]
13. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
[TBL] [Abstract][Full Text] [Related]
14. YKL-40 expression in soft-tissue sarcomas and atypical lipomatous tumors. An immunohistochemical study of 49 tumors.
Harving ML; Christensen LH; Ringsholt M; Lausten GS; Petersen MM
Acta Orthop; 2014 Apr; 85(2):195-200. PubMed ID: 24650028
[TBL] [Abstract][Full Text] [Related]
15. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma.
Thongsom S; Chaocharoen W; Silsirivanit A; Wongkham S; Sripa B; Choe H; Suginta W; Talabnin C
Tumour Biol; 2016 Jul; 37(7):9451-63. PubMed ID: 26781979
[TBL] [Abstract][Full Text] [Related]
16. Role of chitinase-like proteins in cancer.
Kzhyshkowska J; Yin S; Liu T; Riabov V; Mitrofanova I
Biol Chem; 2016 Mar; 397(3):231-47. PubMed ID: 26733160
[TBL] [Abstract][Full Text] [Related]
17. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers.
Faibish M; Francescone R; Bentley B; Yan W; Shao R
Mol Cancer Ther; 2011 May; 10(5):742-51. PubMed ID: 21357475
[TBL] [Abstract][Full Text] [Related]
18. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
Thöm I; Andritzky B; Schuch G; Burkholder I; Edler L; Johansen JS; Bokemeyer C; Schumacher U; Laack E
Cancer; 2010 Sep; 116(17):4114-21. PubMed ID: 20564116
[TBL] [Abstract][Full Text] [Related]
19. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
20. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer.
Kawada M; Seno H; Kanda K; Nakanishi Y; Akitake R; Komekado H; Kawada K; Sakai Y; Mizoguchi E; Chiba T
Oncogene; 2012 Jun; 31(26):3111-23. PubMed ID: 22056877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
